Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 7, 2020

View Archived Issues

Myelin regulatory factor helps out pancreatic cancer cells

Angiotensin inhibitors for AD prevention

Phase II study of mavrilimumab in giant cell arteritis meets efficacy endpoints

Chiba Prefecture patents new compounds targeting mitochondrial DNA mutations

Cortexyme discloses Porphyromonas gingivalis RgpB inhibitors

University of Maryland synthesizes new Mcl-1 and Bcl-2 dual inhibitors

Inflammatory response gene identified in sepsis

Anlotinib plus pemetrexed beneficial in platinum-resistant epithelial ovarian cancer

University of California identifies new EGFR inhibitors

Early clinical data presented for rebastinib

Fulcrum Therapeutics discovers new EED inhibitors

Nivolumab + cabozantinib in first-line RCC: CheckMate 9ER suggests new standard of care

Phase I data presented for Sym-021 as monotherapy or in combination with Sym-022 or Sym-023

Gut-derived LEAP2 fragment demonstrates beneficial metabolic effects on RYGB

Activity seen in phase Ib study of sintilimab and niraparib in advanced solid tumors

Zenith Epigenetics signs CRADA with NCI to develop ZEN-3694 for cancer

Amgen reports topline phase II results with sotorasib in KRAS G12C-mutant advanced NSCLC

Phase II study of neflamapimod for dementia with Lewy bodies meets primary endpoint

NexImmune initiates phase I/II trial of NEXI-002 in multiple myeloma

Avrobio licenses gene therapy for Hunter's syndrome from University of Manchester

Eureka Therapeutics begins phase I/II trial of T-cell therapy in HCC

Pharmacokinetic data on AbFero's iron chelator SP-420 support planned phase I/II study

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...